Mission Statement

To understand how brain tumors develop in children and identify personalized treatment strategies.

Specific Aims

1.    To conduct early phase clinical trials in children with CNS malignancies, with the goal to target specific pathways or molecularly characterized alterations with drugs or strategies specific to each patient
2.    To coordinate the translation of pre-clinical laboratory findings into new therapeutic strategies for children with CNS malignancies

In order to achieve our Specific Aims and ensure we fulfil our Mission Statement, PNOC has developed a set of Core Values and Strategic Pillars that operationally guides the Consortium’s priorities and scientific decisions.

Our Core Values:



Our Core Values are driven by the need to quickly address the significant unmet need of children and young adults with CNS tumors with a set of guiding principles.  We will conduct experiments often, fail fast, learn quickly from our mistakes and try again.  We will work rapidly, quickly translating discoveries in the lab to the bedside, and then get the data back to our labs in real time.  We do not believe we should remain constrained by study conduct only within North America, and we will reach out to other countries and continents to complete studies quickly. We believe collectively, and globally we can push for breakthroughs and remain bold, pushing boundaries, being both safe and disruptive, not constrained by conservative strategies of the past, with the understanding that the stakes are high and incremental results are not our goal.  Our stakeholders are our patients and their families.  Being innovative, collaborative and bold are critical to the mission of PNOC.

PNOC Strategic Pillars

Essential to our Mission, Specific Aims, and Core Values, are the following key Strategic Pillars that inform our day-to-day operations:

1. TRANSLATIONAL BRIDGE TO BEDSIDE: In a commitment to improving the lives of children affected by CNS tumors, PNOC will only perform rapidly translatable studies that are based on strong scientific data, that are biologically and clinically interrogatable for success and failure, and that maximize a collaborative shared resource environment for accelerative preclinical development.

2. DISEASE FOCUS: PNOC will focus on bold and innovative approaches to disease states with unmet needs that we are uniquely positioned to tackle.

3. CLINICAL TRIAL CONDUCT: To offer broad access globally to innovative, patient-centered therapies through agile clinical trial implementation and expanded eligibility criteria to improve outcomes in young people with CNS tumors.

The PNOC leadership, Member Institutions and PNOC Scientific Committee, with support from the Operations Office will collectively ensure we remain true to our Core Values and guiding Strategic Pillars, in order to fulfil our Specific Aims and Mission Statement.

About PNOC

The Pacific Pediatric Neuro-Oncology Consortium (PNOC) was formed to provide children with brain tumors access to innovative treatments. What sets us apart is that we pursue clinical strategies that are based on the molecular and genetic make-up of each tumor. We test therapies aimed at interfering with specific cellular pathways or mutations after confirming that a patient’s tumor has those characteristics, sparing patients therapy that is not optimized for their tumor type. 

We are a consortium with global presence. We have study sites across Australia, through a collaboration with the Australian and New Zealand Children's Hematology/Oncology Group (ANZCHOG); Canada, through C17, a network of seventeen pediatric hematology, oncology, and stem cell transplant programs across Canada; Switzerland and the Netherlands,  key patient catchment areas in Europe: and seventeen sites across the United States. The teams at each of PNOC’s participating hospitals are made up of specialists in different areas of pediatric brain tumor treatment – such as oncology, neurosurgery, and radiation therapy – who combine their expertise to optimize care for each patient. The teams also include nurses, social workers, psychologists, and hospital staff with an in-depth understanding of the needs of families and children suffering from brain tumors. Finally, each site has scientists actively engaged in laboratory research on pediatric tumor biology who work with clinicians to turn their findings into therapies.

The Operations Office for PNOC is supported by the PNOC Foundation and the Pediatric Brain Tumor Foundation.

  • 225 Pediatric Brain Tumor Specialists
  • 16 clinical trials

Our Reach:




United States

PI Spotlight

Rebecca Loret de Mola, DO, MCR
Dr. Rebecca Loret de Mola is an Assistant Professor in the Department of Pediatric Hematology/Oncology at OHSU Doernbecher Children’s Hospital. She has a specific interest in improving the treatment and outcomes for adolescent and young adult patient with central nervous system tumors.